In This Article:
A week ago, Intellia Therapeutics, Inc. (NASDAQ:NTLA) came out with a strong set of yearly numbers that could potentially lead to a re-rate of the stock. Revenues were better than expected, with US$58m in revenue some 11% ahead of forecasts. The company still lost US$5.25 per share, although the losses were marginally smaller than the analysts expected. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.
View our latest analysis for Intellia Therapeutics
Taking into account the latest results, the current consensus, from the 19 analysts covering Intellia Therapeutics, is for revenues of US$47.1m in 2025. This implies an uncomfortable 19% reduction in Intellia Therapeutics' revenue over the past 12 months. The loss per share is expected to ameliorate slightly, reducing to US$4.92. Before this earnings announcement, the analysts had been modelling revenues of US$50.5m and losses of US$5.14 per share in 2025. So there seems to have been a moderate uplift in analyst sentiment with the latest consensus release, given the upgrade to loss per share forecasts for this year.
The consensus price target was broadly unchanged at US$48.54, implying that the business is performing roughly in line with expectations, despite adjustments to both revenue and earnings estimates. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. Currently, the most bullish analyst values Intellia Therapeutics at US$106 per share, while the most bearish prices it at US$10.00. With such a wide range in price targets, analysts are almost certainly betting on widely divergent outcomes in the underlying business. With this in mind, we wouldn't rely too heavily the consensus price target, as it is just an average and analysts clearly have some deeply divergent views on the business.
These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Intellia Therapeutics' past performance and to peers in the same industry. These estimates imply that revenue is expected to slow, with a forecast annualised decline of 19% by the end of 2025. This indicates a significant reduction from annual growth of 0.7% over the last five years. Compare this with our data, which suggests that other companies in the same industry are, in aggregate, expected to see their revenue grow 20% per year. It's pretty clear that Intellia Therapeutics' revenues are expected to perform substantially worse than the wider industry.